9 completed, 1 active not recruiting, 1 recruiting. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Completed 9, Active not recruiting 1, Recruiting 1 |
Follow Qsymia: new trials by email Literature Review of Qsymia trials Research Report on Qsymia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder Group Therapy Program, semaglutide, Phentermine-Topiramate - Bipolar I Disorder, Bipolar II Disorder | Phase 4 | Recruiting | Mayo Clinic | 100 | 2026-01-19 | 2026-03-11 |
| Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide - Obesity | Phase 4 | Active not recruiting | The Cleveland Clinic | 150 | 2025-03-01 | 2026-09-30 |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Semaglutide, Orlistat, Phentermine/Topiramate - Obesity | Phase 4 | Completed | Novo Nordisk A/S | 500 | 2023-01-19 | 2026-01-14 |
| A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects VI-0521, Phentermine, Placebo - Blood Pressure | Phase 4 | Completed | VIVUS LLC | 565 | 2022-01-25 | 2024-07-17 |
| Phase IV Study of Qsymia in Obese Patients Qsymia 3.75Mg-23Mg Extended Release Capsule, Qsymia 7.5Mg-46Mg Extended Release Capsule, Qsymia 11.25Mg-69Mg Extended Release Capsule - Obesity | Phase 4 | Completed | Alvogen Korea | 232 | 2021-09-17 | 2024-01-31 |
| Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker Phentermine-Topiramate Extended Release, Placebo, Online support system - Obesity | Phase 4 | Completed | Mayo Clinic | 80 | 2020-06-03 | 2023-06-22 |
| A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification - Adolescent Obesity, Obesity in Adolescence | Phase 4 | Completed | VIVUS LLC | 223 | 2019-05-02 | 2022-09-10 |
| A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents Placebo, VI-0521 Mid Dose, VI-0521 Top Dose - Pediatric Obesity, Childhood Obesity | Phase 4 | Completed | VIVUS LLC | 42 | 2016-03-01 | 2022-08-23 |
| Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects Qsymia, Placebo - Obesity | Phase 4 | Completed | VIVUS LLC | 51 | 2014-08-01 | 2017-11-07 |
| A Toolbox Approach to Obesity Treatment in Primary Care Commercial weight loss program, Colorado Weigh, Meal replacements - Obesity | Phase 4 | Completed | Denver Health and Hospital Authority | 4730 | 2014-01-01 | 2017-08-18 |
| Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients Phentermine-Topiramate ER, Placebo - Obesity | Phase 4 | Completed | Mayo Clinic | 24 | 2013-04-01 | 2015-02-23 |
Obesity (10) · Pediatric Obesity (2) · Weight Loss (2) · Bipolar Disorder (1) · Overweight (1) · Psychotic Disorders (1)
VIVUS LLC (4) · Mayo Clinic (3) · Alvogen Korea (1) · Denver Health and Hospital Authority (1) · Novo Nordisk A/S (1) · The Cleveland Clinic (1)
United States (10) · South Korea (1)
Andres Acosta, MD, PhD (1) · Bartolome Burguera, M.D (1) · ChangBeom Lee, M.D., Ph.D. (1) · Chris Galloway, MD (1) · Daniel H Bessesen, MD (1) · Daniel Hsia, M.D. (1) · Mark A Frye, M.D. (1) · Michael Camilleri, MD (1)
PMID 25486131, PMID 30257072, PMID 31485965, PMID 36968652, PMID 38304225, PMID 40518455, PMID 41562388
R01DK067071 (1), UL1TR000135 (1)